B族链球菌：全球发病率与疫苗研发
Group B Streptococcus: global incidence and vaccine development.
作者信息
Johri Atul Kumar, Paoletti Lawrence C, Glaser Philippe, Dua Meenakshi, Sharma Puja Kumari, Grandi Guido, Rappuoli Rino
机构信息
School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India.
出版信息
Nat Rev Microbiol. 2006 Dec;4(12):932-42. doi: 10.1038/nrmicro1552. Epub 2006 Nov 6.
Abstract
An ongoing public health challenge is to develop vaccines that are effective against infectious diseases that have global relevance. Vaccines against serotypes of group B Streptococcus (GBS) that are prevalent in the United States and Europe are not optimally efficacious against serotypes common to other parts of the world. New technologies and innovative approaches are being used to identify GBS antigens that overcome serotype-specificity and that could form the basis of a globally effective vaccine against this opportunistic pathogen. This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens.
摘要
一项持续存在的公共卫生挑战是研发出对具有全球影响的传染病有效的疫苗。针对在美国和欧洲流行的B族链球菌（GBS）血清型的疫苗，对世界其他地区常见的血清型的效果并不理想。新技术和创新方法正被用于识别GBS抗原，这些抗原可克服血清型特异性，并可能成为针对这种机会性病原体的全球有效疫苗的基础。本综述重点介绍了为实现这一目标所做的努力，并描述了一种可遵循的模板，用于研发针对其他细菌病原体的疫苗。
相似文献
1
Group B Streptococcus: global incidence and vaccine development.B族链球菌：全球发病率与疫苗研发
Nat Rev Microbiol. 2006 Dec;4(12):932-42. doi: 10.1038/nrmicro1552. Epub 2006 Nov 6.
2
Surface Structures of Group B Important in Human Immunity.B 组表面结构在人类免疫中起重要作用。
Microbiol Spectr. 2019 Mar;7(2). doi: 10.1128/microbiolspec.GPP3-0001-2017.
3
Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.αC蛋白作为III型荚膜多糖的载体以及B族链球菌疫苗中的保护性蛋白。
Infect Immun. 1999 May;67(5):2491-6. doi: 10.1128/IAI.67.5.2491-2496.1999.
4
Prevention of systemic infections caused by group B streptococcus and Staphylococcus aureus by multivalent polysaccharide-protein conjugate vaccines.多价多糖-蛋白结合疫苗预防B族链球菌和金黄色葡萄球菌引起的全身感染
Ann N Y Acad Sci. 1995 May 31;754:68-82. doi: 10.1111/j.1749-6632.1995.tb44439.x.
5
The soluble antigens of GBS as human vaccines.作为人类疫苗的B族链球菌可溶性抗原。
Antibiot Chemother (1971). 1985;35:291-5. doi: 10.1159/000410382.
6
Capsular switching in group B Streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development.B 群链球菌 CC17 超强毒力克隆的荚膜转换：多糖疫苗开发的未来挑战。
J Infect Dis. 2012 Dec 1;206(11):1745-52. doi: 10.1093/infdis/jis605. Epub 2012 Sep 21.
7
Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis.产妇预防时代的B族链球菌与早发型败血症
Pediatr Clin North Am. 2009 Jun;56(3):689-708, Table of Contents. doi: 10.1016/j.pcl.2009.04.003.
8
Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women.孕妇中针对 B 型链球菌直肠阴道定植的血清型特异性自然获得性体液免疫。
Clin Microbiol Infect. 2015 Jun;21(6):568.e13-21. doi: 10.1016/j.cmi.2015.01.030. Epub 2015 Feb 10.
9
Vaccine prevention of group B streptococcal disease.B族链球菌病的疫苗预防
Pediatr Ann. 1993 Dec;22(12):711-4. doi: 10.3928/0090-4481-19931201-05.
10
Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.母体 B 群链球菌免疫接种：荚膜多糖（CPS）疫苗及其在预防方面的意义。
Vaccine. 2011 May 12;29(21):3729-30. doi: 10.1016/j.vaccine.2011.02.102. Epub 2011 Mar 15.
引用本文的文献
1
Harnessing subtractive genomics for drug target identification in Streptococcus agalactiae serotype v (atcc baa-611 / 2603 v/r) strain: An in-silico approach.利用消减基因组学鉴定无乳链球菌血清型V（ATCC BAA-611 / 2603 V/R）菌株中的药物靶点：一种计算机模拟方法。
PLoS One. 2025 Aug 21;20(8):e0319368. doi: 10.1371/journal.pone.0319368. eCollection 2025.
2
The challenge of antimicrobial resistance in the Asia-Pacific: a pediatric perspective.亚太地区抗菌药物耐药性挑战：儿科视角
Curr Opin Pediatr. 2025 Apr 1;37(2):116-123. doi: 10.1097/MOP.0000000000001437. Epub 2025 Feb 4.
3
Pathogenic characterization and drug resistance of neonatal sepsis in China: a systematic review and meta-analysis.中国新生儿败血症的病原学特征与耐药性：一项系统评价与Meta分析
Eur J Clin Microbiol Infect Dis. 2025 Apr;44(4):779-788. doi: 10.1007/s10096-025-05048-1. Epub 2025 Jan 24.
4
Structural and functional analysis reveals the catalytic mechanism and substrate binding mode of the broad-spectrum endolysin Ply2741.结构与功能分析揭示了广谱溶菌酶Ply2741的催化机制和底物结合模式。
Virulence. 2025 Dec;16(1):2449025. doi: 10.1080/21505594.2024.2449025. Epub 2025 Jan 14.
5
Infection in Wild Trahira () and Farmed Arapaima () in Brazil: An Interspecies Transmission in Aquatic Environments Shared with Nile Tilapia ().巴西野生巴西狼脂鲤（Trahira）和养殖巨骨舌鱼（Arapaima）的感染：与尼罗罗非鱼（Nile Tilapia）共享水生环境中的种间传播
Microorganisms. 2024 Nov 22;12(12):2393. doi: 10.3390/microorganisms12122393.
6
Exploiting the Zebrafish Model for Sepsis Research: Insights into Pathophysiology and Therapeutic Potentials.利用斑马鱼模型进行脓毒症研究：对发病机制和治疗潜力的深入了解。
Drug Des Devel Ther. 2024 Nov 22;18:5333-5349. doi: 10.2147/DDDT.S500276. eCollection 2024.
7
A novel chimeric endolysin Cly2v shows potential in treating streptococci-induced bovine mastitis and systemic infections.一种新型嵌合溶菌酶Cly2v在治疗链球菌引起的牛乳腺炎和全身感染方面显示出潜力。
Front Microbiol. 2024 Oct 18;15:1482189. doi: 10.3389/fmicb.2024.1482189. eCollection 2024.
8
Isolation and characterization of Streptococcus agalactiae inducing mass mortalities in cultured Nile tilapia (Oreochromis niloticus) with trials for disease control using zinc oxide nanoparticles and ethanolic leaf extracts of some medicinal plants.分离和鉴定致尼罗罗非鱼大规模死亡的无乳链球菌，并试用氧化锌纳米粒子和几种药用植物的乙醇叶提取物进行疾病控制试验。
BMC Vet Res. 2024 Oct 15;20(1):468. doi: 10.1186/s12917-024-04298-z.
9
Group B streptococcus colonization in pregnancy and neonatal outcomes: a three-year monocentric retrospective study during and after the COVID-19 pandemic.妊娠期 B 群链球菌定植与新生儿结局：COVID-19 大流行期间及之后三年的单中心回顾性研究。
Ital J Pediatr. 2024 Sep 13;50(1):175. doi: 10.1186/s13052-024-01738-2.
10
Unmutated but T cell dependent IgM antibodies targeting Streptococcus suis play an essential role in bacterial clearance.针对猪链球菌的未突变但依赖 T 细胞的 IgM 抗体在清除细菌方面发挥着重要作用。
PLoS Pathog. 2024 Jan 19;20(1):e1011957. doi: 10.1371/journal.ppat.1011957. eCollection 2024 Jan.
本文引用的文献
1
TWO SEROLOGICAL TYPES OF GROUP B HEMOLYTIC STREPTOCOCCI WITH RELATED, BUT NOT IDENTICAL, TYPE-SPECIFIC SUBSTANCES.B 群溶血性链球菌的两种血清型，具有相关但不相同的型特异性物质。
J Exp Med. 1938 Jan 1;67(1):25-40. doi: 10.1084/jem.67.1.25.
2
A SEROLOGICAL DIFFERENTIATION OF SPECIFIC TYPES OF BOVINE HEMOLYTIC STREPTOCOCCI (GROUP B).牛溶血性链球菌（B 群）的血清学分型鉴别。
J Exp Med. 1934 Mar 31;59(4):441-58. doi: 10.1084/jem.59.4.441.
3
Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease.使用表达B族链球菌菌毛的乳酸乳球菌作为预防链球菌疾病的广谱疫苗。
J Infect Dis. 2006 Aug 1;194(3):331-40. doi: 10.1086/505433. Epub 2006 Jun 30.
4
Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae.无乳链球菌中编码抗原性菌毛样结构的新型基因组岛的鉴定。
Mol Microbiol. 2006 Jul;61(1):126-41. doi: 10.1111/j.1365-2958.2006.05225.x.
5
Assembly and role of pili in group B streptococci.B族链球菌菌毛的组装及其作用
Mol Microbiol. 2006 Jun;60(6):1401-13. doi: 10.1111/j.1365-2958.2006.05190.x.
6
Pili in gram-positive pathogens.革兰氏阳性病原体中的菌毛。
Nat Rev Microbiol. 2006 Jul;4(7):509-19. doi: 10.1038/nrmicro1443.
7
Post-genomic vaccine development.后基因组时代的疫苗开发。
FEBS Lett. 2006 May 22;580(12):2985-92. doi: 10.1016/j.febslet.2006.04.084. Epub 2006 May 4.
8
Genomic diversity and evolution within the species Streptococcus agalactiae.无乳链球菌种内的基因组多样性与进化
Microbes Infect. 2006 Apr;8(5):1227-43. doi: 10.1016/j.micinf.2005.11.010. Epub 2006 Jan 19.
9
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome".无乳链球菌多种致病分离株的基因组分析：对微生物“泛基因组”的影响
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13950-5. doi: 10.1073/pnas.0506758102. Epub 2005 Sep 19.
10
Group B streptococcal infections in elderly adults.老年成人中的B族链球菌感染
Clin Infect Dis. 2005 Sep 15;41(6):839-47. doi: 10.1086/432804. Epub 2005 Aug 16.
Zotero 插件